
Japanese pharmaceutical company Daiichi Sankyo Co. announced Monday it had agreed to acquire US company Ambit Biosciences for $410 million.
The company said the move was a bid to establish its presence in the oncology field. Oncology is a branch in medicine that deals with tumors.
The Japanese company will need to spend $315 million to acquire all the stocks of Ambit Biosciences, a joint statement said. Sankyo President Joji Nakayama said in the statement that the move will ensure Sankyo will continue to provide innovative pharmaceuticals in areas that are unmet in terms of medical need.
GMT 09:47 2018 Tuesday ,23 January
SAP unveils big push into French tech start-upsGMT 05:07 2018 Tuesday ,23 January
Noble Group shares surge 37 percent on buyout talksGMT 19:07 2018 Monday ,22 January
BAKS spent Dh225m on charity projects in 2017GMT 22:52 2018 Sunday ,21 January
French firm "recalls baby milk product"GMT 22:27 2018 Sunday ,21 January
US company plans funds that double bitcoin price movesGMT 21:23 2018 Sunday ,21 January
Pence starts Mideast tour in Egypt amid Arab angerGMT 08:54 2018 Saturday ,20 January
Million-euro bill for firm behind Paris bike-share chaosGMT 10:47 2018 Friday ,19 January
German chemical giant BASF sees 'significant' profit leap

Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2025 ©
Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2025 ©
Send your comments
Your comment as a visitor